Αποτελέσματα Αναζήτησης
Since 2013, the standard first-line regimen for HIV treatment has been tenofovir disoproxil fumarate (TDF) combined with efavirenz (EFV), and lamivudine (3TC) or emtricitabine (FTC). This regimen has a low resistance barrier, with 5–8% developing resistance to EFV-based regimens [2].
Costs. Drug prices were: generic F/TDF: $360/year ; branded F/TAF: $16,800/year . The upper bound price of CAB-LA was modeled as $25,850/year (assuming parity with current pricing for HIV treatment using CAB-LA combined with long-acting rilpivirine (RPV-LA)) (22–24) (Appendix Methods).
9 Αυγ 2022 · In the United States, the commercial price for cabotegravir has been set at $3,700 per dose (equivalent to an annual price of $22,200 per person). The not-for-profit price is yet to be made...
There is keen interest in assessing the economic value of using newer, more expensive drugs compared with older, less expensive drugs that have established clinical safety and efficacy.
10 Ιουλ 2024 · Twice-yearly injections of Lenacapavir showed overwhelming efficacy for preventing HIV infections compared to standard oral preventative HIV medicines, known as pre-exposure prophylaxis (PrEP). Additional trials are ongoing in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States.
14 Οκτ 2022 · Two posters presented at AMCP Nexus 2022 addressed the cost-effectiveness of guideline-recommended integrase strand transfer inhibitor–based triple therapy in people living with HIV, as well as...
5 Αυγ 2022 · According to a preprint 2 from Lise Jamieson, a biostatistician at the University of the Witwatersrand in Johannesburg, and her colleagues, posted in March this year, each injection would need to...
